VivoSeq
Oncology

Head and Neck Carcinoma

28

Pipeline Programs↗

5

Active Trials↗

15

Companies Involved↗

Head and Neck Carcinoma is an emerging landscape with 28 programs across 15 companies. The most active players are Neutron Therapeutics, LLC, AstraZeneca, Pfizer. 1 therapy is approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

23/100

Completion Rate

60/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

N

Neutron Therapeutics, LLC

1 program

Phase 1AstraZeneca logo

AstraZeneca

3 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2O

Oncolytics Biotech

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2G

Glaxo Dba Glaxosmithkline

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

16 of 24 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody833%

Small molecule leads; the ring shows all 24 classified programs, each share of the total. Modality classified for 96% of 28 pipeline programs.

Analysis

Trial Status

15

clinical trials

Completed6 · 40%
Recruiting3 · 20%
Terminated3 · 20%
Active, not recruiting2 · 13%
Withdrawn1 · 7%

Clinical Trials

Trial Activity

15 trials

Accelerator-based BNCT (Boron Neutron Capture Therapy) for Head and Neck Carcinoma.
Recruiting·NNeutron Therapeutics, LLC·Phase 1·NCT07058116·10 enrolled
[68Ga]Ga-FAPI-46 in Staging of Head and Neck Carcinomas
Recruiting·—·Phase 2·NCT06794372·20 enrolled
Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma
Recruiting·CCentre Leon Berard·Phase 3·NCT06706401·460 enrolled
SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma
Active, not recruiting·RTOG Foundation, Inc.·Phase 2·NCT03546582·86 enrolled
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Active, not recruiting·—·Phase 1/2·NCT03283605·45 enrolled
Intravenous Versus Subcutaneous Amifostine in Prevention of Xerostomia After RT for Head and Neck Carcinomas
Completed·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 3·NCT00158691·296 enrolled
Effect of Iressa With/Without Concurrent Chemoradiotherapy on Tumor Gene Expression Profiles in Patients With Advanced Non-Nasopharyngeal Head and Neck Carcinoma
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00228488·60 enrolled
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT02105636·361 enrolled
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Completed·OOncolytics Biotech·Phase 2·NCT00753038·14 enrolled
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Completed·SSanford Health·Phase 2·NCT01386632·50 enrolled
ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma
Completed·TThe Netherlands Cancer Institute·Phase 1/2·NCT03003637·33 enrolled
Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma
Terminated·UUniversity of Miami·Phase 2·NCT01794845·5 enrolled
A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma
Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00872404·37 enrolled
Efficacy of SU 011248 in Head And Neck Carcinoma
Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT00408252·54 enrolled
Selective IMRT for Locally Advanced Head and Neck Carcinoma With Concurrent Panitumumab
Withdrawn·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01312493

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)